Qiming Venture Partners, established in 2006, is a leading China-based venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, and Singapore. It manages multiple funds totaling $9.5 billion, focusing on early and growth-stage investments in the Technology and Consumer (T&C) and Healthcare industries. With a strong track record, over 200 portfolio companies have achieved exits, and over 70 have become unicorns or super unicorns. Qiming Venture Partners USA, founded in 2017, is its affiliate in Cambridge, Massachusetts, specializing in healthcare, therapeutics, and digital health investments. The firm is known for its deep technical expertise, hands-on operational support, and thought leadership in the venture capital industry.
Room3906 Jinmao Tower, 88 Century Boulevard, Shanghai 200121, China
Zhang Ao
Executive Director
Artavazd Arumov Ph.D
Principal
Ryan Baker
CFO
Cyrus Chan
Associate
Nan Chen
Principal
David Chu
Partner
Isaac Ciechanover
Partner
Phil DiGiacomo
Principal
Anna French
Managing Partner
Yuxin Fu
Vice President
Jinda Gao
Principal
Kuantai Yeh
Partner
Robert Headley
Partner
Maykin Ho
Venture Partner
William Hu
Managing Partner
Duane Kuang
Co-Founder and Managing Partner
Nisa Leung
Managing Partner
Dingzheng Li
Vice President
Jing Liu
Vice President
Chang Liu
Associate
Bin Liu
Vice President
Biao Lu
Associate
Shuo Mao
Principal
Will McConnell
Principal
Gary Rieschel
Founder and Managing Partner
James Shen
Venture Partner
Motao Sun
Vice President
Amy Tang
Venture Partner
Yi Tang
Principal
Shiyu Wang
Partner
Rachel Wang
Venture Partner
James Wang
Venture Partner
Gillian Xu
RMB funds CFO
Peter (Ming) Yin
Principal, Cleantech
Janet Yu
Partner
Oscar Zhang
Principal
Yafeng Zhou
Associate
Alex Zhou
Managing Partner
Zhiyuan Zhou
Associate
Zhifeng Zhou
Managing Partner
Jing-Shan Hu Ph.D
Venture Partner of Healthcare
Phillip DiGiacomo Ph.D
Principal
Past deals in Series E
TOPI Imaging Technology
Series E in 2025
TOPI Imaging Technology is a medical device firm providing OCT retinal diagnostic system and sweep optical biometer.
DK Medtech
Series E in 2024
DK Medtech, founded in 2015 and headquartered in Suzhou, China, specializes in the development and production of balloon catheter medical devices. The company is recognized as a leader in the medical device industry, focusing on innovative technologies that aim to meet the evolving challenges in healthcare. Through its commitment to excellence, DK Medtech strives to create impactful solutions that enhance patient care and improve medical outcomes.
XSKY Data Technology
Series E in 2021
XSKY Data Technology, based in Beijing, specializes in software-defined infrastructure products and services. It offers a range of storage solutions, including XCBS (cloud), XEBS (block), XEUS (unified), XEOS (object), and XEDP (unified data platform), catering to diverse sectors such as finance, enterprise, telecom, energy, and government. XSKY is a significant contributor to the open-source Ceph storage system, ranking top 3 globally. It partners with leading tech companies like Intel and Samsung, providing scalable, cost-effective storage solutions tailored for enterprise data center innovation.
Delta Medical
Series E in 2021
Beijing Delta Medical Co., Ltd. specializes in the design and manufacture of orthopedic surgical instruments and rehabilitation products. The company offers a range of products, including shoulder arthroscopic instruments, various types of suture anchors, instruments for anterior and posterior cruciate ligament reconstruction, interference screws, and shaver systems. In addition to its surgical instruments, Delta Medical provides sports rehabilitation services. The company is headquartered in Beijing, China, and focuses on delivering innovative solutions in sports medicine.
Miaoshou Doctor
Series E in 2021
Miaoshou Doctor is a healthcare service platform established in 2015 by Tao He and Daoliang Han, headquartered in Beijing. The company focuses on facilitating communication between patients and healthcare professionals, enabling effective management of post-diagnosis outcomes. Its platform empowers doctors to actively monitor their patients' health through ongoing counseling and prescription support, enhancing the overall patient care experience. By streamlining interactions and follow-ups, Miaoshou Doctor aims to improve health outcomes and foster better relationships between patients and their healthcare providers.
Beijing Yuan Xin
Series E in 2021
Beijing Yuanxin is a technology company that offers an integrated healthcare platform for pharmaceutical distribution and health insurance.
Erwan Technology
Series E in 2021
Erwan Technology is an online education provider based in Dalian Shi, Liaoning, China, specializing in financial investment education for Chinese middle-class families. Founded in 2016, the company offers a variety of paid educational modules, including live broadcasts, boutique investment courses, and hands-on workshops, aimed at equipping users with essential financial skills. With a focus on making financial education accessible, Erwan Technology has reached over 10 million middle-class students across 34 provincial administrative regions, establishing itself as the largest online investment education platform by user base and ranking among the top three platforms by revenue. The company’s mission is to enhance financial literacy by covering topics such as investment strategies, risk management, and wealth management.
New Horizon Health
Series E in 2020
New Horizon Health is a biotechnology company based in Hangzhou, China, with an additional office in Beijing, specializing in the development of innovative technologies for early cancer detection and screening. Founded in 2015, the company primarily focuses on gastrointestinal cancers, offering products such as the ColoClear and Pupu Tube, which utilize fecal gene analysis (FIT-DNA) technology for colorectal cancer screening. These products enable users to conduct in-home tests, allowing for the early detection of colon cancer and precancerous lesions that may not be identified through traditional blood tests. New Horizon Health aims to reduce cancer morbidity and mortality rates by promoting accessible and efficient health services, leveraging big data and artificial intelligence in its screening technologies. The company's commitment to early cancer screening reflects its mission to enhance public health by facilitating widespread access to vital diagnostic tools.
Mafengwo
Series E in 2019
Mafengwo is a prominent Chinese travel social networking site that facilitates the sharing of travel experiences among users. The platform boasts over one million entries of user-generated travel guides and more than five million ratings and reviews, catering to a diverse array of travel-related needs, including information on hotels, flights, travel routes, visas, and insurance. Since its inception, Mafengwo has served over 25 million users, emphasizing user experience by continually enhancing its social platform for sharing travel information. Its core product, the Travel Guide, encompasses more than 95% of global travel destinations and has surpassed 100 million downloads. In 2012, Mafengwo expanded its offerings by integrating booking services from major platforms such as Booking, Agoda, Ctrip, and eLong, further solidifying its position in the travel industry.
Nuvaira
Series E in 2019
Nuvaira, Inc. is a medical device company focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). The company has created a novel, catheter-based Lung Denervation System designed to address airway nerve hyperactivity, a common issue in patients with COPD and asthma. This minimally invasive procedure targets the parasympathetic nerves of the lungs, aiming to enhance lung function, improve exercise capacity, and elevate the quality of life for affected individuals. Founded in 2008 and headquartered in Minneapolis, Minnesota, Nuvaira was previously known as Holaira, Inc. before rebranding in June 2017.
Schrödinger
Series E in 2019
Schrödinger is a healthcare-focused software company that specializes in computational drug design, serving pharmaceutical and biotechnology research sectors. Established in 1990, it offers a powerful computational platform that aids biopharmaceutical and industrial companies, as well as academic and government institutions, in their research efforts globally. Schrödinger operates through two main segments: Software and Drug Discovery. The Software segment supplies solutions aimed at enhancing the drug discovery process across the life sciences and materials science industries. Meanwhile, the Drug Discovery segment generates revenue through a portfolio of preclinical and clinical programs, both independently and through collaborative efforts. The company is committed to advancing science and talent to support its platform and has over 400 employees, engaging with customers and collaborators in more than 70 countries.
Tuhu
Series E in 2018
Tuhu is a prominent integrated online and offline platform for automotive services in China, catering to car owners' diverse needs through a customer-centric model. The company offers same-day or next-day delivery and installation of automobile after-sales products in over 260 cities across mainland China. Tuhu's services are accessible via its website, mobile app, call center, and third-party e-commerce platforms. By streamlining its supply chain and providing a digitalized, on-demand service experience, Tuhu effectively connects car owners, suppliers, and automotive service stores. Its platform accommodates a wide range of passenger vehicle models and fulfills various automotive service demands, including tire and chassis parts replacement, maintenance, repair, and detailing.
Micropoint Bio
Series E in 2018
MicroPoint Bioscience, Inc. is a Chinese company focused on biochip research and development, specializing in vitro point-of-care testing (POCT) equipment and biological diagnostic test reagent cards. The company offers a product line called Lab On a Chip, which utilizes microelectromechanical systems (MEMS) technology to deliver microfluidic bio-diagnostic testing solutions. These products are designed to assist medical care providers in the early diagnosis and monitoring of critical diseases, including vascular diseases and tumors. In addition to medical applications, MicroPoint Bioscience also serves sectors such as environmental protection, food safety, and scientific research, customizing its offerings to meet specific customer needs. Their bedside immediate diagnosis chip and examination instruments aim to provide cost-effective solutions for early disease detection and monitoring.
ACEA Biosciences
Series E in 2018
ACEA Biosciences, Inc., established in 2002 and headquartered in San Diego, California, specializes in developing and commercializing microelectronic sensor systems for cell-based assays, drug discovery, and diagnostics. The company's flagship product, the x-CELLigence System, offers real-time, label-free cell analysis, serving diverse applications such as cell proliferation, cytotoxicity testing, and receptor function monitoring. ACEA's products cater to science research and drug discovery markets, with over 800 customers worldwide and numerous peer-reviewed publications. The company operates a state-of-the-art manufacturing facility in Hangzhou, China, and serves its global clientele as a subsidiary of Agilent Technologies, Inc.
Meituan Bike
Series E in 2017
Meituan Bike, previously known as Mobike, is a Chinese bicycle-sharing service that operates a fully station-less model. Founded in January 2015 by Davis Wang Xiao Feng, Hu Wei Wei, and Xia Yi Ping, the company is headquartered in Beijing. Meituan Bike allows users to easily locate and rent bicycles through a mobile application, facilitating convenient transportation for short urban trips. The bicycles are equipped with smart locks and can be reserved via the app, offering a seamless user experience. In April 2018, the company was acquired by Meituan-Dianping for $2.7 billion and was rebranded as Meituan Bike in January 2019 as part of the integration process. The service has grown significantly since its inception, contributing to the development of urban mobility solutions in China.
CanSinoBIO
Series E in 2017
CanSino Biologics Inc. is a biotechnology company based in Tianjin, China, focused on the research, development, manufacturing, and commercialization of vaccines. The company is actively developing a range of vaccines, including those for Ebola, meningitis, pertussis, and pneumococcal diseases, with multiple candidates currently in various phases of clinical trials. Notable products under development include the recombinant coronavirus vaccine Ad5-nCov, as well as several preclinical stage vaccines targeting adenovirus, Zika virus, meningitis, shingles, and polio. CanSino collaborates with the National Research Council of Canada to advance COVID-19 vaccine initiatives and has a co-development agreement with Precision NanoSystems to create an mRNA lipid nanoparticle vaccine against COVID-19. Founded in 2009, CanSino aims to meet the unmet medical needs in China and other emerging markets by providing high-quality vaccines at affordable prices.
ACEA Biosciences
Series E in 2016
ACEA Biosciences, Inc., established in 2002 and headquartered in San Diego, California, specializes in developing and commercializing microelectronic sensor systems for cell-based assays, drug discovery, and diagnostics. The company's flagship product, the x-CELLigence System, offers real-time, label-free cell analysis, serving diverse applications such as cell proliferation, cytotoxicity testing, and receptor function monitoring. ACEA's products cater to science research and drug discovery markets, with over 800 customers worldwide and numerous peer-reviewed publications. The company operates a state-of-the-art manufacturing facility in Hangzhou, China, and serves its global clientele as a subsidiary of Agilent Technologies, Inc.
Mitralign
Series E in 2015
Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.